Research Analysts Offer Predictions for RVMD Q2 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Research analysts at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for Revolution Medicines in a research report issued on Sunday, June 29th. Leerink Partnrs analyst J. Chang now forecasts that the company will earn ($1.06) per share for the quarter, up from their previous forecast of ($1.17). The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for Revolution Medicines' Q3 2025 earnings at ($1.07) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.34) EPS and FY2026 earnings at ($4.60) EPS.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same quarter in the prior year, the firm posted ($0.70) EPS.

A number of other analysts have also recently commented on RVMD. Needham & Company LLC restated a "buy" rating and issued a $57.00 price target on shares of Revolution Medicines in a research report on Tuesday, June 24th. Guggenheim restated a "buy" rating and set a $80.00 target price on shares of Revolution Medicines in a research note on Wednesday, June 25th. Oppenheimer raised their price target on Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Wedbush reaffirmed an "outperform" rating and issued a $73.00 price objective (up previously from $67.00) on shares of Revolution Medicines in a research note on Tuesday, June 24th. Finally, Stifel Nicolaus decreased their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $67.58.

Revolution Medicines Stock Up 1.6%

RVMD traded up $0.60 during trading on Wednesday, hitting $37.79. The company's stock had a trading volume of 591,531 shares, compared to its average volume of 1,667,234. The firm has a market cap of $7.04 billion, a PE ratio of -9.41 and a beta of 1.06. Revolution Medicines has a one year low of $29.17 and a one year high of $62.40. The business's 50 day simple moving average is $39.61 and its 200-day simple moving average is $39.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Revolution Medicines by 14.7% during the fourth quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock worth $747,799,000 after purchasing an additional 2,185,082 shares in the last quarter. Farallon Capital Management LLC lifted its position in Revolution Medicines by 17.1% during the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock worth $579,498,000 after acquiring an additional 1,931,000 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Revolution Medicines by 8.9% in the 1st quarter. Wellington Management Group LLP now owns 11,787,921 shares of the company's stock worth $416,821,000 after acquiring an additional 966,230 shares during the period. Janus Henderson Group PLC grew its position in Revolution Medicines by 54.5% in the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock valued at $414,777,000 after acquiring an additional 3,346,755 shares in the last quarter. Finally, Baker BROS. Advisors LP raised its stake in shares of Revolution Medicines by 4.9% during the fourth quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock valued at $347,163,000 after purchasing an additional 367,882 shares during the period. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.